Amitiza is a brand name of lubiprostone, approved by the FDA in the following formulation(s):
AMITIZA (lubiprostone - capsule; oral)
Manufacturer: SUCAMPO PHARMS
Approval date: January 31, 2006
Strength(s): 24MCG [RLD]
Manufacturer: SUCAMPO PHARMS
Approval date: April 29, 2008
Strength(s): 8MCG
Has a generic version of Amitiza been approved?
No. There is currently no therapeutically equivalent version of Amitiza available.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Amitiza. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: About generic drugs.
Related Patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
Prostaglandins E and anti ulcers containing same
Patent 5,284,858
Issued: February 8, 1994
Inventor(s): Ueno; Ryuzo & Ueno; Ryuji & Kato; Ichie & Oda; Tomio
Assignee(s): Kabushiki Kaisha Ueno Seiyaku Oyo Kenkyujo
The novel 13, 14-dihydro-15-keto prostaglandins E of the invention have remarkable preventive effects against ulcers. Further, the novel 13,14-dihydro-15-ketoprostaglandins E of the invention have an advatage that they have none of side effects which prostaglandin E intrinsically has, or can remarakably reduce such effects of the prostaglandin E. Therefore, the novel 13, 14-dihydro-15-keto prostaglandins E of the invention are effective for animal and human use for treatment and prevention of ulcers, such as duodenal ulcer and gastric ulcer.Patent expiration dates:
- July 14, 2014✓
- July 14, 2014
Anti-constipation composition
Patent 6,414,016
Issued: July 2, 2002
Inventor(s): Ryuji; Ueno
Assignee(s): Sucampo, A.G.
An object of the present invention is to provide an anti-constipation composition containing a halogenated-bi-cyclic compound as an active ingredient in a ratio of bi-cyclic/mono-cyclic structure of at least 1:1. The halogenated-bi-cyclic compound is represented by Formula (I): where X1 and X2 are preferably both fluorine atoms. The composition can be used to treat constipation without substantive side-effects, such as stomachache.Patent expiration dates:
- September 5, 2020✓
- September 5, 2020✓
- September 5, 2020
Composition and method for stabilizing the same
Patent 6,583,174
Issued: June 24, 2003
Inventor(s): Ryuji; Ueno & Tsuyoshi; Habe
Assignee(s): Sucampo, A.G.
Disclosed is a novel composition comprising a novel bi-cyclic compound, which is expected to be pharmaceutically active, and a glyceride. The stability of the bi-cyclic compound can be improved significantly by dissolving the same in a glyceride.Patent expiration dates:
- October 16, 2020✓
- October 16, 2020
Chloride channel opener
Patent 7,064,148
Issued: June 20, 2006
Inventor(s): Ueno; Ryuji & Cuppoletti; John
Assignee(s): Sucampo AG
Disclosed is a novel use of a prostaglandin compound as a chloride channel opener. According to the instant invention, chloride channels in a mammalian subject can be opened by a prostaglandin compound to facilitate chloride ion transportation.Patent expiration dates:
- August 30, 2022✓
- August 30, 2022✓
- August 30, 2022
Composition and method for stabilizing the same
Patent 7,417,067
Issued: August 26, 2008
Inventor(s): Ueno; Ryuji & Habe; Tsuyoshi
Assignee(s): Sucampo AG
Disclosed is a novel composition comprising a novel bi-cyclic compound, which is expected to be pharmaceutically active, and a glyceride. The stability of the bi-cyclic compound can be improved significantly by dissolving the same in a glyceride.Patent expiration dates:
- October 16, 2020✓
- October 16, 2020
Method for treating abdominal discomfort
Patent 7,795,312
Issued: September 14, 2010
Inventor(s): Ueno; Ryuji & Kuno; Sachiko
Assignee(s): Sucampo AG
A method for treating irritable bowel syndrome in a mammalian subject includes administering an effective amount of 13,14-dihydro-15-keto-16,16-difluoro-18-methyl-prostaglandin E1 or 13,14-dihydro-15-keto-16,16-difluoro-prostaglandin E1, or a salt, ether, ester or amide thereof, to the subject. A method for treating abdominal discomfort associated with irritable bowel syndrome in a mammalian subject includes administering an effective amount of 13,14-dihydro-15-keto-16,16-difluoro-18-methyl-prostaglandin E1 or 13,14-dihydro-15-keto-16,16-difluoro-prostaglandin E1, or a salt, ether, ester or amide thereof, to the subject.Patent expiration dates:
- September 17, 2024✓
- September 17, 2024
Soft-gelatin capsule formulation
Patent 8,026,393
Issued: September 27, 2011
Inventor(s): Hashitera; Yukiko & Hirata; Ryu & Harada; Yasuhiro & Ueno; Ryuji
Assignee(s): Sucampo AG
R-Tech Ueno, Ltd.
The present invention discloses a soft gelatin capsule formulation of a 15-keto-prostaglandin compound, which comprises: a soft gelatin capsule shell comprising gelatin and sugar alcohol as a plasticizer, and a mixture comprising a 15-keto-prostaglandin compound and a pharmaceutically acceptable vehicle which is filled in the shell. By encapsulating the 15-keto-prostaglandin compound in the specified soft gelatin capsule shell, stability of the compound is significantly improved.Patent expiration dates:
- October 25, 2027✓
- October 25, 2027
Anti-constipation composition
Patent 8,071,613
Issued: December 6, 2011
Inventor(s): Ueno; Ryuji
Assignee(s): Sucampo AG
An object of the present invention is to provide an anti-constipation composition containing a halogenated-bi-cyclic compound as an active ingredient in a ratio of bi-cyclic/mono-cyclic structure of at least 1:1. The halogenated-bi-cyclic compound is represented by Formula (I): where X1 and X2 are preferably both fluorine atoms. The composition can be used to treat constipation without substantive side-effects, such as stomachache.Patent expiration dates:
- September 5, 2020✓
- September 5, 2020✓
- September 5, 2020
Composition and method for stabilizing the same
Patent 8,088,934
Issued: January 3, 2012
Inventor(s): Ueno; Ryuji & Habe; Tsuyoshi
Assignee(s): SUCAMPO AG
Disclosed is a novel composition comprising a novel bi-cyclic compound, which is expected to be pharmaceutically active, and a glyceride. The stability of the bi-cyclic compound can be improved significantly by dissolving the same in a glyceride.Patent expiration dates:
- May 18, 2021✓
- May 18, 2021
Composition and method for stabilizing the same
Patent 8,097,649
Issued: January 17, 2012
Inventor(s): Ueno; Ryuji & Habe; Tsuyoshi
Assignee(s): Sucampo AG
Disclosed is a novel composition comprising a novel bi-cyclic compound, which is expected to be pharmaceutically active, and a glyceride. The stability of the bi-cyclic compound can be improved significantly by dissolving the same in a glyceride.Patent expiration dates:
- October 16, 2020✓
- October 16, 2020
Dosage unit comprising a prostaglandin analog for treating constipation
Patent 8,097,653
Issued: January 17, 2012
Inventor(s): Ueno; Ryuji & Patchen; Myra L.
Assignee(s): Sucampo AG
A dosage unit for treating constipation in a human patient is described. The dosage unit of the invention comprises a halogenated prostaglandin analog and a pharmaceutically suitable excipient. The dosage unit relieves constipation without substantial side effects.Patent expiration dates:
- November 14, 2022✓
- November 14, 2022
Anti-constipation composition
Patent 8,114,890
Issued: February 14, 2012
Inventor(s): Ueno; Ryuji
Assignee(s): Sucampo AG
An object of the present invention is to provide an anti-constipation composition containing a halogenated-bi-cyclic compound as an active ingredient in ratio of bi-cyclic/mono-cyclic structure of at least 1:1. The halogenated-bi-cyclic compound is represented by Formula (I): where X1 and X2 are preferably both fluorine atoms. The composition can be used to treat constipation with out substantive side-effects, such as stomachache.Patent expiration dates:
- September 5, 2020✓
- September 5, 2020
Related Exclusivities
Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.
- Exclusivity expiration dates:
- January 31, 2011 - NEW CHEMICAL ENTITY
- April 28, 2011 - NEW STRENGTH
- April 28, 2011 - USE OF AMITIZA (LUBIPROSTONE) 8 MCG TWICE DAILY FOR TREATMENT OF IRRITABLE BOWEL SYNDROME WITH CONSTIPATION IN WOMEN GREATER THAN OR EQUAL TO 18 YEARS OLD
See also...
- Amitiza Consumer Information (Drugs.com)
- Amitiza Consumer Information (Wolters Kluwer)
- Amitiza Consumer Information (Cerner Multum)
- Amitiza Advanced Consumer Information (Micromedex)
- Amitiza AHFS DI Monographs (ASHP)
- Lubiprostone Consumer Information (Wolters Kluwer)
- Lubiprostone Consumer Information (Cerner Multum)
- Lubiprostone Advanced Consumer Information (Micromedex)
- Lubiprostone AHFS DI Monographs (ASHP)
No comments:
Post a Comment